elvitegravir/cobicistat/emtricitabine/tenofovir DF, or EVG/COBI/FTC/TDF

Recommended initial regimen for most people in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily with food. Tablet contains 150 mg of the INSTI elvitegravir boosted by 150 mg cobicistat plus 200 mg emtricitabine and 300 mg tenofovir DF (TDF).

For adults and children 12 years of age and older weighing at least 77 pounds (35 kg).

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney or liver problems. Stribild should not be started in individuals with estimated CrCl less than 70 mL/min and should be discontinued if CrCl decreases to less than 50 mL/min. Stribild is not recommended for patients with severe liver problems, or during pregnancy.


Gilead Sciences, Inc.
(800) GILEAD-5 (445–3235)



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments